» Articles » PMID: 30232406

Cell-based RNAi Screening and High-content Analysis in Primary Calvarian Osteoblasts Applied to Identification of Osteoblast Differentiation Regulators

Overview
Journal Sci Rep
Specialty Science
Date 2018 Sep 21
PMID 30232406
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Osteoblasts are responsible for the maintenance of bone homeostasis. Deregulation of their differentiation is etiologically linked to several bone disorders, making this process an important target for therapeutic intervention. Systemic identification of osteoblast regulators has been hampered by the unavailability of physiologically relevant in vitro systems suitable for efficient RNAi and for differentiation read-outs compatible with fluorescent microscopy-based high-content analysis (HCA). Here, we report a new method for identification of osteoblast differentiation regulators by combining siRNA transfection in physiologically relevant cells with high-throughput screening (HTS). Primary mouse calvarial osteoblasts were seeded in 384-well format and reverse transfected with siRNAs and their cell number and differentiation was assayed by HCA. Automated image acquisition allowed high-throughput analyses and classification of single cell features. The physiological relevance, reproducibility, and sensitivity of the method were validated using known regulators of osteoblast differentiation. The application of HCA to siRNAs against expression of 320 genes led to the identification of five potential suppressors and 60 activators of early osteoblast differentiation. The described method and the associated analysis pipeline are not restricted to RNAi-based screening, but can be adapted to large-scale drug HTS or to small-scale targeted experiments, to identify new critical factors important for early osteoblastogenesis.

Citing Articles

Impaired MC3T3-E1 osteoblast differentiation triggered by oncogenic HRAS is rescued by the farnesyltransferase inhibitor Tipifarnib.

Andrasch Y, Ireri M, Gander J, Timm A, Chennappan S, Fidan M Sci Rep. 2025; 15(1):6832.

PMID: 40000861 PMC: 11861272. DOI: 10.1038/s41598-025-91592-x.


Why Animal Experiments Are Still Indispensable in Bone Research: A Statement by the European Calcified Tissue Society.

Stein M, Elefteriou F, Busse B, Fiedler I, Kwon R, Farrell E J Bone Miner Res. 2023; 38(8):1045-1061.

PMID: 37314012 PMC: 10962000. DOI: 10.1002/jbmr.4868.


Downregulation of the Autism Spectrum Disorder Gene Decreases Bone Mass in Male Mice.

Ahmad M, Stirmlinger N, Jan I, Stifel U, Lee S, Weingandt M JBMR Plus. 2023; 7(2):e10711.

PMID: 36751416 PMC: 9893268. DOI: 10.1002/jbm4.10711.


Inhibition of Cdk5 increases osteoblast differentiation and bone mass and improves fracture healing.

Ahmad M, Kruger B, Kroll T, Vettorazzi S, Dorn A, Mengele F Bone Res. 2022; 10(1):33.

PMID: 35383146 PMC: 8983726. DOI: 10.1038/s41413-022-00195-z.


Inhibition of Cdk5 Ameliorates Skeletal Bone Loss in Glucocorticoid-Treated Mice.

Kruger B, Steppe L, Vettorazzi S, Haffner-Luntzer M, Lee S, Dorn A Biomedicines. 2022; 10(2).

PMID: 35203613 PMC: 8962259. DOI: 10.3390/biomedicines10020404.


References
1.
Rauch A, Gossye V, Bracke D, Gevaert E, Jacques P, Van Beneden K . An anti-inflammatory selective glucocorticoid receptor modulator preserves osteoblast differentiation. FASEB J. 2011; 25(4):1323-32. DOI: 10.1096/fj.10-173393. View

2.
Shearer R, Saunders D . Experimental design for stable genetic manipulation in mammalian cell lines: lentivirus and alternatives. Genes Cells. 2014; 20(1):1-10. DOI: 10.1111/gtc.12183. View

3.
Gresch O, Altrogge L . Transfection of difficult-to-transfect primary mammalian cells. Methods Mol Biol. 2011; 801:65-74. DOI: 10.1007/978-1-61779-352-3_5. View

4.
Siggelkow H, Rebenstorff K, Kurre W, Niedhart C, Engel I, Schulz H . Development of the osteoblast phenotype in primary human osteoblasts in culture: comparison with rat calvarial cells in osteoblast differentiation. J Cell Biochem. 1999; 75(1):22-35. View

5.
MacNabb C, Patton D, Hayes J . Sclerostin Antibody Therapy for the Treatment of Osteoporosis: Clinical Prospects and Challenges. J Osteoporos. 2016; 2016:6217286. PMC: 4899597. DOI: 10.1155/2016/6217286. View